APA

Delaloge S., Pérol D., Courtinard C., Brain E., Asselain B., Bachelot T., Debled M., Dieras V., Campone M., Levy C., Jacot W., Lorgis V., Veyret C., Dalenc F., Ferrero J. M., Uwer L., Kerbrat P., Goncalves A., Mouret-Reynier M. A., Petit T., Jouannaud C., Vanlemmens L., Chenuc G., Guesmia T., Robain M. & Cailliot C. (20180102). Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero J M, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier M A, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M and Cailliot C. 20180102. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Delaloge S., Pérol D., Courtinard C., Brain E., Asselain B., Bachelot T., Debled M., Dieras V., Campone M., Levy C., Jacot W., Lorgis V., Veyret C., Dalenc F., Ferrero J. M., Uwer L., Kerbrat P., Goncalves A., Mouret-Reynier M. A., Petit T., Jouannaud C., Vanlemmens L., Chenuc G., Guesmia T., Robain M. and Cailliot C. (20180102). Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero J M, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier M A, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M and Cailliot C. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. : Annals of oncology : official journal of the European Society for Medical Oncology. 20180102.